- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Peter Jørgensen: The Danish Experience With Biosimilar Adalimumab
Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains the Danish experience with biosimilar adalimumab.
Transcript
I think it's fair to say that it has been very positive. You know, it was introduced not that long ago, less than half a year ago, and the uptake in less than a month was 90%. Not 19%, but 90%.
In effect, Humira, which was by far the biggest pharmaceutical on the Danish market, has been wiped out completely from Danish hospital shelves. You just can’t have Humira anywhere in Denmark anymore. Even though they offered a rebate on 78%, that was not enough to keep them on the market for 2019.
In accordance, the Danish tender system has gone to 2 products where they have offered a rebate of 86%. So on the one hand, you have uptake of 90%, and you have a rebate on 86%. Imagine what that would do not just for the public health, the health economy of the Danish healthcare sector, but also for the patients, because at the same time, since the product has become cheaper, more patients have gotten access to the product.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
How Vertical Integration Drives Innovation and Access in Biosimilars
August 1st 2025Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
August 1st 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Can Global Policies to Boost Biosimilar Adoption Work in the US?
August 1st 2025On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
